AstraZeneca to begin trials for COVID-19 “antibody cocktail” drug treatment

United Kingdom // 21 November, 2020

Large scale phase 3 trials for an antibody drug is likely to begin in the United Kingdom, according to media sources. The drug is designed to protect people with a weakened immune system from COVID-19. The clinical trial will enroll 5,000 participants who are at increased risk of infection or who are more likely to have an inadequate response to vaccination and will include people from health care and care home settings. The aim of the trial is to evaluate the safety and effectiveness of AZD7442, a combination of two long-acting monoclonal antibodies – man-made proteins that act like natural human antibodies in the immune system. The drug is expected to give immediate protection to the recipient and protection could last for six months to a year.

LATEST NEWS

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  • COVID-19 in Eswatini

    Eswatini // 03 December, 2020

    Over 6,000 cases and 120 deaths. Increasing activity...

    COVID-19

  • COVID-19 in Eritrea

    Eritrea // 03 December, 2020

    Over 500 cases. Limited activity...

    COVID-19

  • COVID-19 in Equatorial Guinea

    Equatorial Guinea // 03 December, 2020

    Over 5,000 cases confirmed, and at least 85 deaths. Limited Activity...

    COVID-19

  • COVID-19 in DRC

    Congo DRC // 03 December, 2020

    More than 12,000 cases and over 300 deaths. Limited Activity...

    COVID-19

  • COVID-19 in Cote d'Ivoire

    Cote d'Ivoire // 03 December, 2020

    Over 21,000 cases confirmed. Decreasing activity...

    COVID-19

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
Webinars

Pandemic Information Webinars
(Available to Pandemic Subscribers only)
Register for upcoming events
View/Download previous webinars